Detail akcie Onzima Ventures Rg online

Business Summary: N4 Pharma plc is a United Kingdom-based pre-clinical biotech company. The Company is engaged in developing Nuvec, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. The Company is building out its preclinical dataset and working towards first-in-human clinical data to support licensing deals for its Nuvec platform with gene therapy partners. Its lead program, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept program showcasing all the benefits of the Nuvec platform. ECP105 is a siRNA therapy intended for injection into the ocular cavity and contains a proprietary siRNA sequence to silence the fibrotic gene responsible for fibrosis (MRTF-B), or scarring, which occurs post-surgery. LipTide is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells.
Financial Summary: BRIEF: For the six months ended 30 June 2025, N4 Pharma PLC revenues decreased 6% to L4K. Net loss increased 10% to L499K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions.